Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 203-212 , February 2008

Difference in brain distributions of carbon 11-labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of the NMDA ion channel

  • Takeshi Fuchigami

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
    • Photon Medical Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
    • ,
  • Terushi Haradahira

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 956 20 5714; fax: +81 956 20 5622.
    • ,
  • Noriko Fujimoto

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Takashi Okauchi

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
    • ,
  • Jun Maeda

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
    • ,
  • Kazutoshi Suzuki

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
    • ,
  • Tetsuya Suhara

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Inage-ku, Chiba 263-8555, Japan
    • ,
  • Fumihiko Yamamoto

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Shigeki Sasaki

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Takahiro Mukai

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Hiroshi Yamaguchi

      Affiliations

    • Molecular Imaging Frontier Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
    • ,
  • Mikako Ogawa

      Affiliations

    • Photon Medical Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
    • ,
  • Yasuhiro Magata

      Affiliations

    • Photon Medical Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
    • Molecular Imaging Frontier Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
    • ,
  • Minoru Maeda

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan

Received 19 June 2006 ,Revised 2 October 2007 ,Accepted 17 October 2007.

References 

  1. Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev. 1998;50:597–664
  2. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 1998;11:523–569
  3. Millan MJ. N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology. 2005;179:30–53
  4. Haradahira T, Zhang M-R, Maeda J, Okauchi T, Kida T, Kawabe K, et al. A prodrug of NMDA/glycine site antagonist, L-703,717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog. Chem Pharm Bull. 2001;49:147–150
  5. Matsumoto R, Haradahira T, Ito H, Fujimura Y, Seki C, Ikoma Y, et al. Measurement of glycine binding site of N-methyl-D-asparate (NMDA) receptors in living human brain using 4-acetoxy derivative of L-703,717, 4-acetoxy-7-chloro-3-[3-(4-[11C] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with positron emission tomography. Synapse. 2007;61:795–800
  6. Haradahira T, Suzuki K. An improved synthesis of [11C]L-703,717 as a radioligand for the glycine site of the NMDA receptors. Nucl Med Biol. 1999;26:245–247
  7. Opacka-Juffery J, Morris H, Ashworth S, Osman S, Hirani E, Macleod AM, et al. Preliminary evaluation of the glycine site antagonists [11C]L-703,717 and [3H]MDL105,519 as putative PET ligands for central NMDA receptors: in vivo studies in rats. Quant Func Brain Imaging PET. 1998;299–303
  8. Haradahira T, Suhara S, Okauchi T, Maeda J, Arai T, Sasaki S, et al. Developments of PET radioligands for NMDA receptors. World J Nucl Med. 2002;1:S183–S184
  9. Chapman AG, Dürmüller N, Harrison BL, Baron BM, Parvez N, Meldrum BS. Anticonvulsant activity of a novel NMDA/glycine site antagonist, MDL 104,653 against kindled and sound-induced seizures. Eur J Pharmacol. 1995;274:83–88
  10. Rowley M, Kulagowski JJ, Watt AP, Rathbone D, Stevenson GI, Carling RW, et al. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem. 1997;40:4053–4068
  11. Haradahira T, Okauchi T, Maeda J, Zhang M-R, Kida T, Kawabe K, et al. A positron-emitter labeled glycineB site antagonist, [11C]L-703,717, preferentially binds to a cerebellar NMDA receptor subtype consisting of GluR ε3 subunit in vivo, but not in vitro. Synapse. 2002;43:131–133
  12. Haradahira T, Okauchi T, Maeda J, Zhang M-R, Nishikawa T, Konno R, et al. Effects of endogenous agonists, glycine and D-serine, on in vivo specific binding of [11C]L-703,717, a PET radioligand for the glycine-binding site of NMDA receptors. Synapse. 2003;50:130–136
  13. Buchstaller H-P, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, et al. Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitor of [3H]glycine binding to N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006;49:864–871
  14. Kulagowski JJ, Rowley M, Leeson PD, Mawer IM. Hydroquinolone derivatives. EP0481676 1992;15–33.
  15. Rowley M, Leeson PD, Stevenson GI, Moseley AM, Stansfield I, Sanderson I, et al. 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex. J Med Chem. 1993;36:3386–3396
  16. Haradahira T, Maeda J, Okauchi T, Zhang M-R, Hojo J, Kida T, et al. Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (±)threo-1-(4-hydroxyphenyl)-2-[4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors. Nucl Med Biol. 2002;29:517–525
  17. Danysz W, Kozela E, Parsons CG, Sladek M, Bauer T, Popik P. Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance. Neuropharmacology. 2005;48:360–371
  18. Haradahira T, Zhang M-R, Maeda J, Okauchi T, Kawabe K, Kida T, et al. A strategy for increasing the brain uptake of a radioligand in animals: use of drug that inhibits plasma protein binding. Nucl Med Biol. 2000;27:357–360
  19. Mugnaini M, Antolini M, Corsi M, van Amsterdam F. [3H]5,7-dichlorokynurenic acid recognizes two binding sites in rat cerebral cortex membranes. J Recept Signal Transduct Res. 1998;18:91–112
  20. Mugnaini M, Dal Forno G, Corsi M, Bunnemann B. Receptor binding characteristics of the novel NMDA receptor glycine site antagonist [3H]GV150526A in rat cerebral cortical membranes. Eur J Pharmacol. 2000;391:233–241
  21. Grimwood S, Moseley AM, Carling RW, Leeson PD, Foster AC. Characterization of the binding of [3H]L-698,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol. 1992;41:923–930
  22. Monaghan DT, Olverman HJ, Nguyen L, Watkins JC, Cotman CW. Two classes of N-methyl-D-aspartate recognition sites: differential distribution and differential regulation by glycine. Proc Natl Acad Sci U S A. 1988;85:9836–9840
  23. Kuryatov A, Laube B, Betz H, Kuhse J. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron. 1994;12:1291–1300
  24. Wafford KA, Kathoria M, Bain CJ, Marshall G, Le Bourdellés B, Kemp JA, et al. Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine-binding site. Mol Pharmacol. 1995;47:374–380
  25. O'Shea RD, Manallack DT, Conway EL, Mercer LD, Beart PM. Evidence for heterogenous glycine domains but conserved multiple states of the excitatory amino acid recognition site of the NMDA receptor: regional binding studies with [3H]glycine and [3H]L-glutamate. Exp Brain Res. 1991;86:652–662
  26. Yamakura T, Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol. 1999;59:279–298
  27. Masu M, Nakajima Y, Moriyoshi K, Ishii T, Akawawa C, Nakanishi S. Molecular characterization of NMDA and metabotropic glutamate receptors. Ann N Y Acad Sci. 1993;707:153–164
  28. Grimwood S, Le Bourdellés B, Whiting PJ. Recombinant human NMDA homomeric NR1 receptors expressed in mammalian cells form a high-affinity glycine antagonist-binding site. J Neurochem. 1995;64:525–530
  29. Siegel BW, Sreekrishna K, Baron BM. Binding of the radiolabeled glycine site antagonist [3H]MDL 105,519 to homomeric NMDA-NR1a receptors. Eur J Pharmacol. 1996;312:357–365
  30. Baron BM, Siegel BW, Harrison BL, Gross RS, Hawes C, Towers P. [3H]MDL 105,519, a high-affinity radioligand for the N-methyl-D-aspartate receptor-associated glycine recognition site. J Pharmacol Exp Ther. 1996;279:62–68
  31. Chopra B, Chazot PL, Stephenson FA. Characterization of the binding of two novel glycine site antagonists to cloned NMDA receptors: evidence for two pharmacological classes of antagonists. Br J Pharmacol. 2000;130:65–72
  32. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Muzuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 1991;354:31–37
  33. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 1992;256:1217–1221
  34. Kashiwagi K, Pahk AJ, Masuko T, Igarashi K, Williams K. Block and modulation of N-methyl-d-aspartate receptors by polyamines and protons: role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits. Mol Pharmacol. 1997;52:701–713
  35. Hashemzadeh-Gargari H, Guilarte TR. Divalent cations modulate N-methyl-d-aspartate receptor function at the glycine site. J Pharmacol Exp Ther. 1999;290:1356–1362
  36. Pangalos MN, Francis PT, Foster AC, Pearson RCA, Middlemiss DN, Bowen DM. NMDA receptor assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurons. Brain Res. 1992;596:223–230
  37. Wamsley JK, Sofia RD, Faull RLM, Ary T, Narang N, McCabe RT. Use of [3H]5,7 dichlorokynurenic acid to identify strychnine-insensitive glycine receptors in human postmortem brain. Brain Res Bull. 1994;35:205–209
  38. Jang C-G, Park Y, Rockhold RW, Ho IK. Autoradiographic study of NMDA-displaceable [3H]glutamate and [3H]MK-801 binding during butorphanol withdrawal in the rat brain. Brain Res. 1999;845:236–241
  39. Honer M, Benke D, Laube B, Kuhse J, Heckendorn R, Allgeier H, et al. Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. J Biol Chem. 1998;273:11158–11163

PII: S0969-8051(07)00255-7

doi: 10.1016/j.nucmedbio.2007.10.007

Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 203-212 , February 2008

Article Tools

* Image Usage & Resolution